Human IL-1ra/IL-1F3 Antibody

Catalog #: AB-280-NA Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AB-280-NA

IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutral-ization by Human IL‑1ra/IL‑1F3 Antibody.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IL-1ra/IL-1F3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human IL‑1ra/IL-1F3 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse IL‑1ra/IL‑1F3, recombinant rat IL-1ra/IL-1F3, recombinant porcine IL‑1ra/IL-1F3, and recombinant equine IL‑1ra/IL-1F3 is observed, and less than 1% cross-reactivity with recombinant human (rh) IL-1a, rhIL-1b, rhIL-18, and rhIL-1H1 is observed.

Source

Polyclonal Goat IgG

Purification

Protein A or G purified

Immunogen

E. coli-derived recombinant human IL‑1ra/IL-1F3
Arg26-Glu177
Accession # P18510

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human IL‑1ra/IL‑1F3 (Catalog # 280-RA)

Neutralization

Measured by its ability to neutralize IL‑1ra/IL‑1F3 inhibition of IL‑1 alpha /IL‑1F1-dependent proliferation in the D10.G4.1 mouse helper T cell line [Symons, J.A. et al. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 272]. The Neutralization Dose (ND₅₀) is typically 5-10 µg/mL in the presence of 50 ng/mL Recombinant Human IL‑1ra/IL‑1F3, 50 pg/mL Recombinant Human IL‑1 alpha /IL‑1F1.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IL‑1ra/IL‑1F3 Inhibition of IL‑1 alpha /IL‑1F1-dependent Cell Proliferation and Neutral-ization by Human IL‑1ra/IL‑1F3 Antibody. Recombinant Human IL-1ra/IL-1F3 (Catalog # 280-RA) inhibits Recombinant Human IL-1a/IL-1F1 (Catalog # 200-LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL-1a/IL-1F1 (50 pg/mL) activity elicited by Recombinant Human IL-1ra/IL-1F3 (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-1ra/IL-1F3 Polyclonal Antibody (Catalog # AB-280-NA). The ND₅₀ is typically 5-10 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-1ra/IL-1F3

IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha. It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

Long Name

Interleukin 1 Receptor Antagonist

Entrez Gene IDs

3557 (Human); 16181 (Mouse); 60582 (Rat); 397499 (Porcine)

Alternate Names

DIRA; ICIL-1ra; IL1F3; IL-1F3; IL1ra; IL-1ra; IL-1ra3; IL1RN; IL-1RN; interleukin 1 receptor antagonist; IRAP; MVCD4